Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.59 |
| ▸ | SRD5A1 | P18405 | 15/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6943997 | 0.73 | SRD5A1 (1.00) | NOTUMSRD5A1HTR2CHTR2BHSD17B3 | |
| SCHEMBL6823141 | 0.72 | SRD5A1 (1.00) | NOTUMSRD5A1HSD17B3 | |
| SCHEMBL6946819 | 0.69 | HTR2C (0.56) | NOTUMSRD5A1HTR2CHTR2B | |
| SCHEMBL6820051 | 0.67 | SRD5A1 (0.64) | NOTUMSRD5A1 | |
| SCHEMBL4713862 | 0.65 | NOTUM (0.62) | NOTUMSRD5A1HTR2CHTR2B | |
| SCHEMBL8858028 | 0.64 | HTR2C (0.51) | NOTUMSRD5A1HTR2CHTR2BHSD17B3 | |
| SCHEMBL15964553 | 0.64 | AADAT (0.50) | NOTUMSRD5A1 | |
| SCHEMBL20344483 | 0.64 | SRD5A1 (0.50) | NOTUMSRD5A1 | |
| SCHEMBL7051403 | 0.63 | SRD5A1 (1.00) | NOTUMSRD5A1HSD17B3 | |
| SCHEMBL6944630 | 0.63 | SRD5A1 (1.00) | NOTUMSRD5A1HSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6555549-B2 | Useful in treating acne, baldness, prostatic cancer and hypertrophy in men and hirsutism in women | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-04-29 | — | — | US | claimed |
| EP-0999747-B1 | USE OF BENZO[C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-04-23 | — | — | EP | claimed |
| EP-0880520-B1 | BENZO [C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5-ALPHA-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-04-16 | — | — | EP | claimed |
| US-6514912-B1 | Use of benzo[C]quinolizine derivatives as plant growth regulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-02-04 | — | — | US | claimed |
| US-20010047098-A1 | Benzo[c]quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | MERCK SERONO SA (CH) | 2001-11-29 | — | — | US | claimed |
| US-20010044542-A1 | Benzo [c] quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | MERCK SERONO SA (CH) | 2001-11-22 | — | — | US | claimed |
| EP-0999747-A1 | USE OF BENZO C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2000-05-17 | — | — | EP | claimed |
| WO-1999005913-A1 | USE OF BENZO[C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1999-02-11 | — | — | WO | claimed |
| US-6555549-B2 | Useful in treating acne, baldness, prostatic cancer and hypertrophy in men and hirsutism in women | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-04-29 | — | — | US | disclosed |
| EP-0999747-B1 | USE OF BENZO[C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-04-23 | — | — | EP | disclosed |
| US-6552034-B2 | Cyclization of a silylated butadiene reacted with a 2-oxo-1,2,3,4-tetrahydroquinoline; acne; alopecia; prostatic cancer and hypertrophy; hirsutism in women; skin and glandular disorders; anticarcinogenic agents | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-04-22 | — | — | US | disclosed |
| EP-0880520-B1 | BENZO [C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5-ALPHA-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-04-16 | — | — | EP | disclosed |
| US-6514912-B1 | Use of benzo[C]quinolizine derivatives as plant growth regulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-02-04 | — | — | US | disclosed |
| US-20010047098-A1 | Benzo[c]quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | MERCK SERONO SA (CH) | 2001-11-29 | — | — | US | disclosed |
| US-20010044542-A1 | Benzo [c] quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | MERCK SERONO SA (CH) | 2001-11-22 | — | — | US | disclosed |
| US-6303622-B1 | FOR THERAPY OF ACNE, BALDNESS, PROSTATE CANCER, PROSTATIC HYPERTROPHY; HIRSUTISM | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2001-10-16 | — | — | US | disclosed |
| EP-0999747-A1 | USE OF BENZO C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005913-A1 | USE OF BENZO[C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044542-A1 | Benzo [c] quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | CYP3A5, CYP51A1, CYP2F1 | NOTUM 551/4885SRD5A1 8/4885HTR2C 531/4885 |
| US-20010047098-A1 | Benzo[c]quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | CYP3A5, CYP51A1, CYP2F1 | NOTUM 551/4885SRD5A1 8/4885HTR2C 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.